Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MGTA 117

Next Previous
Drug Profile

MGTA 117

Alternative Names: Anti-CD117 amanitin ADC - Dianthus Therapeutics; Anti-CD117 amanitin antibody drug conjugate - Dianthus Therapeutics; CD117-amanitin antibody drug conjugate - Dianthus Therapeutics; MGTA 117

Latest Information Update: 27 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard University; Heidelberg Pharma AG
  • Developer Dianthus Therapeutics
  • Class Antianaemics; Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Peptides
  • Mechanism of Action RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Haemoglobinopathies; Lysosomal storage diseases; Myelodysplastic syndromes

Most Recent Events

  • 25 Mar 2024 Discontinued - Phase-I/II for Acute myeloid leukaemia (Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
  • 25 Mar 2024 Discontinued - Phase-I/II for Myelodysplastic syndromes (Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
  • 25 Mar 2024 Discontinued - Preclinical for Haemoglobinopathies in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top